Contrasting effects of sunitinib within in vivo models of metastasis
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Contrasting effects of sunitinib within in vivo models of metastasis
Authors
Keywords
-
Journal
ANGIOGENESIS
Volume 15, Issue 4, Pages 623-641
Publisher
Springer Nature
Online
2012-07-28
DOI
10.1007/s10456-012-9291-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
- (2012) Vesselina G. Cooke et al. CANCER CELL
- Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy
- (2012) A. McIntyre et al. CLINICAL CANCER RESEARCH
- Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
- (2012) S. J. Conley et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
- (2012) Barbara Sennino et al. Cancer Discovery
- Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy
- (2011) D. Y. Heng et al. ANNALS OF ONCOLOGY
- Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer
- (2011) Irfan Kayani et al. CLINICAL CANCER RESEARCH
- Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
- (2011) Annika Armulik et al. DEVELOPMENTAL CELL
- MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
- (2011) James Finke et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Growing tumor vessels: More than one way to skin a cat – Implications for angiogenesis targeted cancer therapies
- (2011) Rodrigo Leite de Oliveira et al. MOLECULAR ASPECTS OF MEDICINE
- Morphology, Attenuation, Size, and Structure (MASS) Criteria: Assessing Response and Predicting Clinical Outcome in Metastatic Renal Cell Carcinoma on Antiangiogenic Targeted Therapy
- (2010) Andrew Dennis Smith et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
- (2010) Jennifer S. Ko et al. CANCER RESEARCH
- Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma
- (2010) D. Huang et al. CANCER RESEARCH
- Mechanisms of resistance to antiangiogenesis therapy
- (2010) Faisal Azam et al. EUROPEAN JOURNAL OF CANCER
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Is there really a yin and yang to VEGF-targeted therapies?
- (2010) Lee M Ellis et al. LANCET ONCOLOGY
- Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib
- (2010) J C Welti et al. ONCOGENE
- Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CT
- (2009) Andrew Dennis Smith et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
- (2009) Kristy J. Gotink et al. ANGIOGENESIS
- Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy
- (2009) S. J. Priceman et al. BLOOD
- Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
- (2009) Sonja Loges et al. CANCER CELL
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
- (2009) Brett E. Houk et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy
- (2009) J. M. L. Ebos et al. CLINICAL CANCER RESEARCH
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Resistance to targeted therapy in renal-cell carcinoma
- (2009) Brian I Rini et al. LANCET ONCOLOGY
- The nuances of therapy
- (2009) Lee M. Ellis et al. NATURE
- Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer
- (2009) R J DeBerardinis et al. ONCOGENE
- Mechanisms of Cancer Cachexia
- (2009) Michael J. Tisdale PHYSIOLOGICAL REVIEWS
- Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition
- (2008) D. T. Dang et al. CANCER RESEARCH
- Refractoriness to Antivascular Endothelial Growth Factor Treatment: Role of Myeloid Cells
- (2008) F. Shojaei et al. CANCER RESEARCH
- The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?
- (2008) Ferry ALM Eskens et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2008) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started